EGFR-Mutant Lung Cancer Clinical Trial Landscape

Key trials in EGFR-mutant NSCLC

The table below reflects recruiting trials registered on ClinicalTrials.gov targeting EGFR-mutant non-small cell lung cancer as of early 2026. DataLookout monitors for new registrations and status changes daily.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting trials as of early 2026.

EGFR mutations in NSCLC: the most common targetable driver

EGFR (epidermal growth factor receptor) mutations are the most frequently identified targetable genetic alterations in non-small cell lung cancer, present in approximately 15% of NSCLC patients in the United States. In East Asian populations, the prevalence is substantially higher — reaching 40–50% in lung adenocarcinoma. Globally, that translates to over 200,000 new EGFR-mutant NSCLC diagnoses per year, making it one of the largest molecularly defined oncology patient populations and one of the most intensely drug-developed.

The clinically actionable EGFR mutations fall into two primary categories:

• Classical (sensitizing) mutations: Exon 19 deletions (~45% of EGFR mutations) and L858R point mutation in exon 21 (~40%). These mutations constitutively activate EGFR signaling and sensitize tumors to EGFR tyrosine kinase inhibitors (TKIs). Standard EGFR TKIs — and osimertinib in particular — show durable responses in these patients.
• Uncommon mutations: G719X (exon 18), S768I (exon 20), L861Q (exon 21), and exon 20 insertions. Uncommon sensitizing mutations may respond to second-generation TKIs (afatinib) or newer agents. Exon 20 insertions, however, are generally resistant to standard EGFR TKIs and require dedicated therapies such as mobocertinib or amivantamab (which has activity in exon 20 insertion).

HER2 exon 20 insertions are a distinct molecular entity — despite sharing the exon 20 insertion mechanism, they require different treatment (trastuzumab deruxtecan, not EGFR TKIs) and are not captured under the EGFR-mutant label in clinical trials. This distinction matters when reviewing trial eligibility criteria.

Current standard of care: osimertinib as the dominant first-line EGFR TKI

Osimertinib (Tagrisso, AstraZeneca) is the established global standard of care for first-line treatment of EGFR-mutant NSCLC with classical mutations. It is a third-generation, mutant-selective, covalently binding EGFR TKI with proven CNS penetration — an important property given the high rate of brain metastases in EGFR-mutant NSCLC.

The FLAURA phase 3 trial established osimertinib's superiority over first-generation TKIs (gefitinib/erlotinib): median progression-free survival of 18.9 months versus 10.2 months, with an overall survival benefit (38.6 months vs. 31.8 months). Osimertinib's coverage of the T790M resistance mutation — the most common mechanism of resistance to first-generation TKIs — meant it could serve as both first-line therapy and sequencing strategy, eventually making the older TKI-to-osimertinib sequence largely obsolete for most patients.

Osimertinib is also approved in the adjuvant setting. The ADAURA trial demonstrated a significant disease-free survival benefit after complete resection of EGFR-mutant NSCLC (stages IB–IIIA), with a hazard ratio of 0.17 in stage II–IIIA patients. This drove broad adoption of adjuvant EGFR TKI therapy, and the Beamion LUNG-3 trial (NCT07195695) is now testing whether zongertinib can improve on this in the same setting.

As of early 2026, amivantamab plus lazertinib (Rybrevant + Lazcluze, J&J) received FDA approval as a first-line option based on the MARIPOSA trial, which showed superior progression-free survival versus osimertinib in EGFR exon 19 deletion or L858R patients (23.7 months vs. 16.6 months). This is the first bispecific antibody-based first-line regimen in EGFR-mutant NSCLC and directly competes with osimertinib, adding complexity to the treatment landscape for newly diagnosed patients.

Zongertinib: the most watched EGFR TKI challenge (Beamion LUNG-2 and LUNG-3)

Zongertinib (BI 1810631, Boehringer Ingelheim) is the most closely followed experimental EGFR TKI in the 2026 pipeline. Two concurrent Phase 3 trials are testing zongertinib in distinct settings:

Beamion LUNG-2 (NCT06151574) — first-line, head-to-head vs. osimertinib

Beamion LUNG-2 is a global Phase 3 trial comparing zongertinib directly against osimertinib as first-line therapy in EGFR-mutant NSCLC with classical mutations. This is a direct superiority attempt — not a non-inferiority design — which sets a high scientific bar. Zongertinib differentiates from osimertinib in two key ways: it has demonstrated activity against EGFR exon 20 insertion mutations (which osimertinib largely lacks), and it carries a differentiated resistance profile that may delay or alter the emergence of C797S and other resistance mechanisms. If Beamion LUNG-2 reads out positively, it would represent the first successful head-to-head challenge to osimertinib in the first-line setting.

Beamion LUNG-3 (NCT07195695) — adjuvant post-surgery vs. osimertinib

Running in parallel, Beamion LUNG-3 tests zongertinib in the adjuvant setting against osimertinib following complete resection of EGFR-mutant NSCLC. The adjuvant setting is commercially valuable because patients remain on therapy for up to three years, and the population is enriched for patients who may have longer survival horizons. A win in adjuvant would open a major commercial opportunity independent of the metastatic result.

Firmonertinib: next-generation EGFR TKI from ArriVent BioPharma

Firmonertinib (furmonertinib, FURMONERTINIB) is a third-generation EGFR TKI initially developed by Allist Pharmaceuticals in China, where it received approval (as Arfuqing) in 2021. ArriVent BioPharma licensed global rights and is running a U.S.-focused Phase 3 trial (NCT07185997) comparing firmonertinib against investigator's choice in patients who have progressed on prior EGFR TKI therapy.

Firmonertinib demonstrated a 74% objective response rate in treatment-naive EGFR-mutant NSCLC in Chinese Phase 3 data (FURLONG trial), with median PFS of 20.8 months — numerically competitive with osimertinib but in a different patient population and trial context. Its CNS penetration data and activity in T790M-positive patients are key differentiators being evaluated in the U.S. program. Whether firmonertinib can carve out a commercial position in a market dominated by osimertinib will depend on the Phase 3 readout and any differentiated safety or resistance profile data.

The ADC revolution: post-TKI EGFR treatment enters a new paradigm

The two most consequential Phase 3 trials for post-osimertinib EGFR-mutant NSCLC involve antibody-drug conjugates (ADCs) — a mechanistic departure from TKI sequencing that is reshaping how oncologists and sponsors think about second-line treatment.

Sacituzumab tirumotecan (MK-2870): TROP2 ADC in post-EGFR TKI NSCLC

Sacituzumab tirumotecan (MK-2870, Merck/Kelun-Biotech) is a TROP2-directed ADC that is being tested in two concurrent Phase 3 trials in EGFR-mutant NSCLC. NCT06305754 compares MK-2870 against pemetrexed plus carboplatin chemotherapy in patients who have progressed on an EGFR TKI — the most common second-line scenario. NCT06422143 tests MK-2870 combined with pembrolizumab as maintenance therapy after platinum-based chemotherapy.

TROP2 is broadly expressed in NSCLC regardless of mutation status, making sacituzumab tirumotecan a mutation-agnostic approach. The comparator in NCT06305754 (pemetrexed/carboplatin) represents the current second-line standard for many post-TKI patients, giving this trial a clean commercial relevance: if MK-2870 wins, it would likely displace standard chemotherapy in this setting. Phase 1/2 data showed an objective response rate of approximately 40% in EGFR-mutant patients, warranting the Phase 3 investment.

Izalontamab brengitecan (BMS-986507): HER3 ADC from Bristol-Myers Squibb

Izalontamab brengitecan (BMS-986507) is a HER3-directed ADC from BMS that entered Phase 2/3 testing (NCT07100080) in EGFR-mutant NSCLC patients post-EGFR TKI, compared against platinum-pemetrexed chemotherapy. HER3 overexpression is common in EGFR-mutant NSCLC and has been explored as a resistance mechanism — HER3 signaling can bypass EGFR inhibition and may be upregulated as tumors acquire TKI resistance. This biologic rationale makes HER3 a particularly attractive post-TKI ADC target in this population.

The key competitive question is how HER3 ADCs will compare with TROP2 ADCs in this setting. Both NCT06305754 (Merck) and NCT07100080 (BMS) use similar comparators and patient populations, meaning eventual cross-trial comparison will be closely watched. If both succeed, patient selection based on HER3 vs. TROP2 expression levels may determine which agent is preferred.

Amivantamab + lazertinib: bispecific antibody approved first-line

Amivantamab (Rybrevant, J&J) is a bispecific antibody targeting both EGFR and MET — two of the most important resistance pathways in EGFR-mutant NSCLC. Combined with lazertinib (a third-generation EGFR TKI), the MARIPOSA trial demonstrated superior progression-free survival versus osimertinib alone (23.7 months vs. 16.6 months, HR 0.70) in previously untreated EGFR exon 19 deletion or L858R NSCLC.

The FDA approved amivantamab plus lazertinib in August 2024, making it the first approved first-line alternative to osimertinib for classical EGFR-mutant NSCLC. The regimen is given subcutaneously after the initial IV loading cycle (subcutaneous formulation approved), improving administration convenience. The MARIPOSA-2 trial also established amivantamab plus chemotherapy as a post-osimertinib option, meaning amivantamab is now active across multiple lines of therapy.

The MET component of amivantamab is particularly relevant because MET amplification is one of the most common resistance mechanisms to osimertinib (~15% of cases). This mechanistic fit gives amivantamab a rationale for patients who develop osimertinib resistance via MET-dependent pathways.

EGFR resistance mechanisms: what happens when TKIs stop working

Resistance to osimertinib is the defining challenge in EGFR-mutant NSCLC drug development. Unlike first-generation TKI resistance (which was largely explained by a single gatekeeper mutation, T790M), osimertinib resistance is mechanistically heterogeneous — which is why no single drug has yet dominated the post-osimertinib space.

• C797S (EGFR-dependent resistance): This mutation in the EGFR cysteine-797 residue prevents covalent binding by osimertinib. No drug is currently approved for C797S-driven resistance. Multiple fourth-generation EGFR TKIs are in early clinical development specifically targeting C797S.
• T790M (gatekeeper mutation): The primary mechanism of first-generation TKI resistance; already covered by osimertinib, so it is not a relevant resistance mechanism for patients who receive osimertinib upfront.
• MET amplification (~15%): A bypass signaling mechanism that can be addressed by amivantamab (bispecific EGFR/MET antibody) or MET-targeted TKIs such as savolitinib in combination with osimertinib.
• EGFR-independent mechanisms: Including KRAS mutations, cell lineage transformation (small cell transformation), RET fusions, and others. These generally require empiric chemotherapy or clinical trial enrollment as there are no mutation-specific approved therapies.

The heterogeneity of osimertinib resistance is why the Phase 3 ADC trials (sacituzumab tirumotecan and izalontamab brengitecan) are taking a target-agnostic approach — they do not require a specific resistance mechanism, instead relying on TROP2 or HER3 surface expression that is present regardless of the underlying resistance driver.

Related clinical trials and monitoring resources

EGFR-mutant NSCLC does not exist in isolation — many trials cross targets and tumor types, and understanding the broader NSCLC landscape is essential for complete competitive intelligence. DataLookout monitors related areas including:

• NSCLC clinical trials — full non-small cell lung cancer pipeline, all mutation subgroups, 128 recruiting trials
• ALK-positive lung cancer clinical trials — parallel TKI development trajectory; lorlatinib standard challenged by neladalkib Phase 3
• ROS1-fusion NSCLC clinical trials — rare (~1–2%) fusion-driven subtype; repotrectinib approved, taletrectinib Phase 3 adjuvant
• HER2-mutant NSCLC clinical trials — exon 20 insertions share biological features with EGFR exon 20; T-DXd approved, zongertinib Phase 3
• Small cell lung cancer clinical trials — relevant because EGFR-mutant NSCLC can transform to SCLC as a resistance mechanism
• KRAS G12C clinical trials — the second-largest targeted mutation population in NSCLC; KRAS G12C and EGFR mutations are mutually exclusive in most patients

Frequently asked questions